JP6023803B2 - 神経変性及び虚血性脳疾患を処置するための化合物及び薬学的組合せ - Google Patents

神経変性及び虚血性脳疾患を処置するための化合物及び薬学的組合せ Download PDF

Info

Publication number
JP6023803B2
JP6023803B2 JP2014517444A JP2014517444A JP6023803B2 JP 6023803 B2 JP6023803 B2 JP 6023803B2 JP 2014517444 A JP2014517444 A JP 2014517444A JP 2014517444 A JP2014517444 A JP 2014517444A JP 6023803 B2 JP6023803 B2 JP 6023803B2
Authority
JP
Japan
Prior art keywords
pcb
seq
peptide
ifn
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014517444A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014520764A5 (enExample
JP2014520764A (ja
Inventor
ロル、ジゼル ペントン
ロル、ジゼル ペントン
アルズアガ、アレクセイ ロピス
アルズアガ、アレクセイ ロピス
プリダ、ハヴィエル マリン
プリダ、ハヴィエル マリン
ペントン　アリアス、エデュアルド
アリアス、エデュアルド ペントン
ジメネス、エフライン ロドリゲス
ジメネス、エフライン ロドリゲス
ラサ、アレクシス ムサッチオ
ラサ、アレクシス ムサッチオ
ペレス、ウラディミール、アルマンド ベサダ
ペレス、ウラディミール、アルマンド ベサダ
アンドリウ ジルベルト、ラザロ パルド
アンドリウ ジルベルト、ラザロ パルド
ロペス、ルイス、ハヴィエル ゴンザレス
ロペス、ルイス、ハヴィエル ゴンザレス
フェンテス、ナンシー パヴォン
フェンテス、ナンシー パヴォン
ニエト、ジェラルド、エンリケ ギレン
ニエト、ジェラルド、エンリケ ギレン
サウラ、ペドロ、アントニオ ロペス
サウラ、ペドロ、アントニオ ロペス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centro de Ingenieria Genetica y Biotecnologia CIGB
Original Assignee
Centro de Ingenieria Genetica y Biotecnologia CIGB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro de Ingenieria Genetica y Biotecnologia CIGB filed Critical Centro de Ingenieria Genetica y Biotecnologia CIGB
Publication of JP2014520764A publication Critical patent/JP2014520764A/ja
Publication of JP2014520764A5 publication Critical patent/JP2014520764A5/ja
Application granted granted Critical
Publication of JP6023803B2 publication Critical patent/JP6023803B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/081—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Alternative & Traditional Medicine (AREA)
JP2014517444A 2011-07-01 2012-06-29 神経変性及び虚血性脳疾患を処置するための化合物及び薬学的組合せ Active JP6023803B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CU2011/0146 2011-07-01
CU2011000146A CU23963B1 (es) 2011-07-01 2011-07-01 Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
PCT/CU2012/000003 WO2013004203A1 (es) 2011-07-01 2012-06-29 Compuestos y combinaciones farmacéuticas para el tratamiento de enfermedades cerebrales isquemicas y neurodegenerativas

Publications (3)

Publication Number Publication Date
JP2014520764A JP2014520764A (ja) 2014-08-25
JP2014520764A5 JP2014520764A5 (enExample) 2015-08-20
JP6023803B2 true JP6023803B2 (ja) 2016-11-09

Family

ID=46614264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014517444A Active JP6023803B2 (ja) 2011-07-01 2012-06-29 神経変性及び虚血性脳疾患を処置するための化合物及び薬学的組合せ

Country Status (18)

Country Link
US (2) US9518085B2 (enExample)
EP (1) EP2733149B9 (enExample)
JP (1) JP6023803B2 (enExample)
KR (1) KR101987978B1 (enExample)
CN (1) CN103649106B (enExample)
AR (1) AR087034A1 (enExample)
AU (1) AU2012280776B2 (enExample)
BR (1) BR112013033970B1 (enExample)
CA (1) CA2838496C (enExample)
CU (1) CU23963B1 (enExample)
DK (1) DK2733149T3 (enExample)
ES (1) ES2601887T3 (enExample)
IN (1) IN2014CN00510A (enExample)
MX (1) MX345534B (enExample)
RU (1) RU2569302C2 (enExample)
SI (1) SI2733149T1 (enExample)
WO (1) WO2013004203A1 (enExample)
ZA (1) ZA201309554B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3013355B1 (en) * 2013-06-25 2019-08-07 ICM - Institut du Cerveau et da la Moelle Epinière Il-2 for use in treating alzheimer disease and related disorders
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
RU2613765C1 (ru) * 2016-01-26 2017-03-21 Федеральное государственное автономное образовательное учреждение высшего образования "Северо-Восточный федеральный университет им. М.К.Аммосова" Способ лечения спиноцеребеллярной атаксии
CN108752445B (zh) * 2018-06-20 2021-04-30 广东药科大学 一种螺旋藻蛋白的制备工艺及其神经保护用途
KR102152407B1 (ko) * 2019-02-26 2020-09-07 (주)나우코스 스피루리나에서 유래한 파이코시아노블린 및 이의 유도체를 유효성분으로 포함하는 화장료 조성물
KR20210091664A (ko) 2020-01-14 2021-07-22 경북대학교 산학협력단 중간엽 줄기세포 유래 단백질을 포함하는 소뇌성운동실조증의 치료 예후를 예측하기 위한 바이오마커, 및 이를 이용한 소뇌성운동실조증의 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5709855A (en) 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
US7025965B1 (en) * 2003-02-12 2006-04-11 Pharma Chemie, Inc. Method of use and dosage composition of bluegreen algae extract for inflammation in animals
WO2004084933A1 (en) * 2003-03-28 2004-10-07 Faron Pharmaceuticals Oy Elevation of adenosine level by cytokine-induced expression of cd73
CU23581A1 (es) * 2005-10-28 2010-10-30 Ct Ingenieria Genetica Biotech Interferon alfa y c-ficocianina para el tratamiento de enfermedades autoinmunes, alérgicas y cáncer
RU2441663C2 (ru) * 2006-06-27 2012-02-10 Нутратек С.Р.Л. Препарат aphanizomenon flos aquae, экстракты и очищенные компоненты экстрактов для лечения неврологических, нейродегенеративных и аффективных расстройств
CA2668757C (en) * 2006-11-13 2016-08-23 Mark Fredrick Mccarty Composition for inhibiting nadph oxidase activity

Also Published As

Publication number Publication date
ES2601887T3 (es) 2017-02-16
CN103649106B (zh) 2016-01-20
MX345534B (es) 2017-02-03
US20140356319A1 (en) 2014-12-04
EP2733149B9 (en) 2019-05-15
KR20140078601A (ko) 2014-06-25
SI2733149T1 (sl) 2017-01-31
BR112013033970B1 (pt) 2022-10-18
RU2569302C2 (ru) 2015-11-20
CU20110146A7 (es) 2013-02-26
DK2733149T3 (en) 2016-11-28
RU2014103246A (ru) 2015-08-10
EP2733149A1 (en) 2014-05-21
IN2014CN00510A (enExample) 2015-04-03
BR112013033970A2 (pt) 2017-02-14
AR087034A1 (es) 2014-02-05
WO2013004203A1 (es) 2013-01-10
US20170119733A1 (en) 2017-05-04
AU2012280776B2 (en) 2016-07-14
CU23963B1 (es) 2013-12-11
JP2014520764A (ja) 2014-08-25
ZA201309554B (en) 2014-08-27
KR101987978B1 (ko) 2019-06-11
AU2012280776A1 (en) 2014-01-23
CA2838496A1 (en) 2013-01-10
MX2013015206A (es) 2014-02-20
US9518085B2 (en) 2016-12-13
CA2838496C (en) 2020-01-07
CN103649106A (zh) 2014-03-19
EP2733149B1 (en) 2016-09-28

Similar Documents

Publication Publication Date Title
JP6023803B2 (ja) 神経変性及び虚血性脳疾患を処置するための化合物及び薬学的組合せ
EP1620124A2 (en) Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders
AU2010203446B2 (en) Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22
JPH04305535A (ja) 細胞増殖抑制作用または細胞毒作用を有する治療用活性物質の組合せ
US20240374570A1 (en) Driving axon regeneration by nrf2 overexpression and edaravone application
JP5936707B2 (ja) インターフェロンおよびアンドログラホリドを用いた多発性硬化症のための併用療法
EP3233102B1 (en) Use of an antimicrobial peptide to induce cell death in breast cancer
AU2019202876B2 (en) Administration of Recombinant Collagen 7 for the Treatment of Age Related Disorders
RU2721282C2 (ru) Способ лечения рассеянного склероза (варианты)
CN109865127B (zh) 经修饰的胸腺素β4在治疗糖尿病周围神经病变方面的用途
RU2461566C1 (ru) Способ лечения злокачественных опухолей у млекопитающих
JP5439007B2 (ja) 血管内皮細胞増殖因子阻害剤及び抗癌剤
CN120939206A (zh) Metrnl蛋白与氯吡格雷联合治疗血栓的药物组合物及其应用
PT1471974E (pt) Factor de necrose tumural combinado com interferão em doenças desmielinizantes
WO2000024414A1 (fr) Agents preventifs/curatifs pour les maladies du foie
HK1238166A1 (en) Apoaequorin-containing compositions and methods of using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160725

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20161007

R150 Certificate of patent or registration of utility model

Ref document number: 6023803

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250